Susan Izzo
Family · Vernon, CTNPI 1881644631
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 1,049 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,049 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Novo Nordisk$2K
- AstraZeneca$1K
- GSK$871
- Lilly USA, LLC$830
- Amgen$819
- plus $8K from 54 others
What the payments were for
- Food & beverage$17,26099%
- Education$1051%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$17,365 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 74 | $135,224 |
| JardianceEmpagliflozin | 51 | $74,118 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $64,826 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $51,274 |
| JanuviaSitagliptin Phosphate | 48 | $49,347 |
| FarxigaDapagliflozin Propanediol | 42 | $43,679 |
| RybelsusSemaglutide | 32 | $35,627 |
| ProliaDenosumab | 15 | $26,672 |
| EliquisApixaban | 15 | $25,581 |
| LinzessLinaclotide | 12 | $19,673 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $19,081 |
| MyrbetriqMirabegron | 17 | $16,651 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $16,560 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $10,436 |
| XareltoRivaroxaban | 12 | $10,098 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,791 | $170,851106 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $871 | $84,35972 claims |
| Boehringer IngelheimJardiance | $405 | $74,11851 claims |
| MerckJanuvia, Janumet | $138 | $68,42867 claims |
| AstraZenecaFarxiga | $1,408 | $43,67942 claims |
| AbbVieLinzess, Synthroid, Savella | $3,061 | $26,71469 claims |
| AmgenProlia | $819 | $26,67215 claims |
| PfizerEliquis | $730 | $25,58115 claims |
| Astellas Pharma US IncMyrbetriq | $442 | $16,65117 claims |
| Johnson & JohnsonXarelto | $466 | $10,09812 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $55 | $1,771168 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.
Other family in Vernon
- Jennifer JeromeVernon$9K
- Jude HallVernon$8K
- Elisha ChristiansonWaterbury$371K
- Kathryn TierneyNew Britain$140K
- Jennifer SilvaSouth Windsor$91K
- Carli WillardEnfield$74K
- Erin MartinMilford$70K
- Dayna GiordanoNew Haven$65K
- Diana BytyqiDerby$53K
- Farhiya AbdiSouth Windsor$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.